Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Sasanlimab · RN-888

Monoclonal antibody · Inhibitor of Programmed cell death protein 1 (PD-1) (PDCD1) · developed by Pfizer

Phase 3 Most advanced trial
PFE Developer
1 Registered trials

What is Sasanlimab?

Sasanlimab is an antibody that binds the inhibitory receptor PD-1 and blocks its interaction with the ligands PD-L1 and PD-L2, which can restore natural killer cell and cytotoxic T-lymphocyte activity against tumor cells. It is being studied in non-muscle invasive bladder cancer.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
RN-888, PF-06801591
Drug type
Monoclonal antibody
Targets
Programmed cell death protein 1 (PD-1) (PDCD1)
Mechanism
Inhibitor of Programmed cell death protein 1 (PD-1) (PDCD1)
Pathways
PD-1/PD-L1 checkpoint signaling, NK cell and cytotoxic T-lymphocyte activation
Therapy area
Oncology
Developer
Pfizer (PFE)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 3
UNII
LZZ0IC2EWP

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT04165317 Phase 3 Non-muscle Invasive Bladder Cancer Active not recruiting PFE

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Non-muscle Invasive Bladder Cancer

Other drugs acting on PDCD1

More from Pfizer

Sources

Updated Nov 22, 2026. Something wrong or missing? Report it on the PFE page.

Follow PFE, the company behind Sasanlimab

See PFE's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

PFE catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.